Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
InhaleRx Limited is an Australian biotechnology company specializing in the development of innovative, registrable inhaled drug-device combinations. The company’s primary objective is to enhance treatment modalities by delivering precise doses of pharmaceutical agents via inhalation, particularly targeting conditions where rapid onset is crucial. InhaleRx is actively working on a clinical pipeline that includes IRX-211, a synthetic cannabinoid (dronabinol) formulated for breakthrough cancer pain, and IRX-616a, which is being developed for panic disorder. Both products leverage pressurised metered dose inhaler (pMDI) technology, offering fixed-dose, convenient, and effective administration. By combining drug formulation innovation with device integration, InhaleRx serves unmet medical needs in the healthcare sector, particularly in pain management and mental health. The company’s work contributes to the broader biotechnology sphere, aiming to provide more immediate relief for patients compared to conventional oral or injectable therapies. Incorporated in 2016 and headquartered in Melbourne, InhaleRx represents a focused player linking biotechnology advances with patient-centered delivery systems within the healthcare equipment and biotechnology industry.